Prognostic factors in breast cancer: one fits all?
暂无分享,去创建一个
[1] W. Alexander,et al. American Society of Clinical Oncology , 2020, Definitions.
[2] E. Berns,et al. Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer. , 2012, Breast.
[3] A. Glas,et al. Impact of mammographic screening on the detection of good and poor prognosis breast cancers , 2011, Breast Cancer Research and Treatment.
[4] J. Coebergh,et al. Variation in management of early breast cancer in the Netherlands, 2003-2006. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[5] Kelly K. Hunt,et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. , 2010, Annals of surgery.
[6] A. Glas,et al. Clinical utility of the 70-gene MammaPrint profile in a Japanese population. , 2010, Japanese journal of clinical oncology.
[7] M. J. van de Vijver,et al. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] A. Luini,et al. Sentinel Lymph Node Biopsy in Breast Cancer: Ten-Year Results of a Randomized Controlled Study , 2010, Annals of surgery.
[9] R. Rosenfeld,et al. Cases , 2010, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[10] L. J. Veer,et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer , 2010, Breast Cancer Research and Treatment.
[11] Annuska M. Glas,et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer , 2010, Breast Cancer Research and Treatment.
[12] L. J. Veer,et al. Metastatic Potential of T1 Breast Cancer can be Predicted by the 70-gene MammaPrint Signature , 2010, Annals of Surgical Oncology.
[13] B. Fisher,et al. The breast cancer alternative hypothesis: is there evidence to justify replacing it? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] S. Mook,et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. , 2009, The Lancet. Oncology.
[15] Laura Esserman,et al. Rethinking screening for breast cancer and prostate cancer. , 2009, JAMA.
[16] A. Hart,et al. Validation of 70-gene prognosis signature in node-negative breast cancer , 2009, Breast Cancer Research and Treatment.
[17] Peter C Gøtzsche,et al. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends , 2009, BMJ : British Medical Journal.
[18] H. Adami,et al. Improved breast cancer survival following introduction of an organized mammography screening program among both screened and unscreened women: a population-based cohort study , 2009, Breast Cancer Research.
[19] R. Gelber,et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] E. Rutgers,et al. MammaPrint 70-gene profile quantifies the likelihood of recurrence for early breast cancer. , 2009, Expert opinion on medical diagnostics.
[21] D. Larsimont,et al. Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial. , 2009, European journal of cancer.
[22] S. Michiels,et al. Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. , 2009, The Lancet. Oncology.
[23] S. Linn,et al. Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature , 2009, British Journal of Cancer.
[24] Angela Fagerlin,et al. Improving understanding of adjuvant therapy options by using simpler risk graphics , 2008, Cancer.
[25] M. Ellis,et al. Recommendations for collection and handling of specimens from group breast cancer clinical trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] H. Welch,et al. The natural history of invasive breast cancers detected by screening mammography. , 2008, Archives of internal medicine.
[27] Carlos Caldas,et al. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer , 2008, Breast Cancer Research.
[28] J. Otten,et al. Impressive time‐related influence of the Dutch screening programme on breast cancer incidence and mortality, 1975‐2006 , 2008, International journal of cancer.
[29] J. Coebergh,et al. Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990-2006 in the southeastern Netherlands. , 2008, European journal of cancer.
[30] Bernard Rachet,et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). , 2008, The Lancet. Oncology.
[31] J. Marks,et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] L. Esserman,et al. Risk communication with patients with breast cancer: cautionary notes about printing Adjuvant! estimates. , 2008, The Lancet. Oncology.
[33] S. Duffy,et al. Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone? , 2008, British Journal of Cancer.
[34] Sridhar Ramaswamy,et al. Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal Cohort , 2008, Clinical Cancer Research.
[35] L. V. van't Veer,et al. Clinical application of the 70-gene profile: the MINDACT trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] R. Peto,et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. , 2008, Lancet.
[37] C. Ingvar,et al. Axillary Recurrence Rate After Negative Sentinel Node Biopsy in Breast Cancer: Three-Year Follow-Up of the Swedish Multicenter Cohort Study , 2008, Annals of Surgery.
[38] J. Nevins,et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. , 2007, The Lancet. Oncology.
[39] Wim H van Harten,et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). , 2007, The Lancet. Oncology.
[40] R. Bast,et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] G. Hortobagyi,et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.
[43] Yi Zhang,et al. Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer , 2007, BMC Cancer.
[44] D. Berry,et al. Breast cancer trends: a marriage between clinical trial evidence and epidemiology. , 2007, Journal of the National Cancer Institute.
[45] J. Bergh,et al. Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series , 2007, Clinical Cancer Research.
[46] Stella Mook,et al. Individualization of therapy using Mammaprint: from development to the MINDACT Trial. , 2007, Cancer genomics & proteomics.
[47] Wim H van Harten,et al. Methodology of constructive technology assessment in health care , 2007, International Journal of Technology Assessment in Health Care.
[48] J. Bergh,et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] J. Coebergh,et al. An overview of prognostic factors for long-term survivors of breast cancer , 2007, Breast Cancer Research and Treatment.
[50] Stefan Michiels,et al. Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? , 2007, European journal of cancer.
[51] J. Couzin. Amid Debate, Gene-Based Cancer Test Approved , 2007, Science.
[52] J. Forbes,et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] P. Ravdin,et al. A decision aid to assist in adjuvant therapy choices for breast cancer , 2006, Psycho-oncology.
[54] A. Witteveen,et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test , 2006, BMC Genomics.
[55] H. Dressman,et al. Genomic signatures to guide the use of chemotherapeutics , 2006, Nature Medicine.
[56] E. Rutgers,et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial , 2006, Nature Clinical Practice Oncology.
[57] S. Hilsenbeck,et al. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] J. Ross,et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] L. V. van't Veer,et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. , 2006, Journal of the National Cancer Institute.
[60] A. Nobel,et al. Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .
[61] M. Cronin,et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] S. Shak,et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients , 2006, Breast Cancer Research.
[63] Ahmedin Jemal,et al. Trends in Breast Cancer by Race and Ethnicity: Update 2006 , 2006, CA: a cancer journal for clinicians.
[64] G. Hortobagyi,et al. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] Roland Eils,et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] J. Foekens,et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] J. Forbes,et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[68] D. Berry,et al. Effect of screening and adjuvant therapy on mortality from breast cancer. , 2006, The New England journal of medicine.
[69] L. Clegg,et al. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] M. J. van de Vijver,et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.
[71] Zhao Chen,et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. , 2005, Journal of the National Cancer Institute.
[72] R. Gelber,et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[73] H. Dai,et al. No common denominator for breast cancer lymph node metastasis , 2005, British Journal of Cancer.
[74] R. Demicheli,et al. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[75] I. Tannock,et al. Should screen-detected breast cancers be managed differently? , 2005, Journal of the National Cancer Institute.
[76] Yu Shen,et al. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. , 2005, Journal of the National Cancer Institute.
[77] W. Sauerbrei,et al. Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.
[78] Roman Rouzier,et al. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.
[79] M. Dowsett,et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] J. Peterse,et al. Breast cancer metastasis: markers and models , 2005, Nature Reviews Cancer.
[81] J. Forbes,et al. BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer , 2005 .
[82] M. J. van de Vijver,et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[84] John Quackenbush,et al. Multiple-laboratory comparison of microarray platforms , 2005, Nature Methods.
[85] Kevin Coombes,et al. Prognostic Role of a Multigene Reverse Transcriptase-PCR Assay in Patients with Node-Negative Breast Cancer Not Receiving Adjuvant Systemic Therapy , 2005, Clinical Cancer Research.
[86] Kathleen F. Kerr,et al. Standardizing global gene expression analysis between laboratories and across platforms , 2005, Nature Methods.
[87] Karen A Gelmon,et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] Howard Y. Chang,et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[89] J. Foekens,et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.
[90] Maurice P H M Jansen,et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] Shinzaburo Noguchi,et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[92] Kenneth H Buetow,et al. Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[93] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[94] Donna Neuberg,et al. Comparison of frozen and RNALater solid tissue storage methods for use in RNA expression microarrays , 2004, BMC Genomics.
[95] R. Carlson,et al. Update: NCCN breast cancer Clinical Practice Guidelines. , 2004, Journal of the National Comprehensive Cancer Network : JNCCN.
[96] C. Halkes,et al. In vivo regulation of plasma free fatty acids in insulin resistance. , 2004, Metabolism: clinical and experimental.
[97] V. Kataja,et al. Risk for distant recurrence of breast cancer detected by mammography screening or other methods. , 2004, JAMA.
[98] H. D. de Koning,et al. Decreased rates of advanced breast cancer due to mammography screening in The Netherlands , 2004, British Journal of Cancer.
[99] Roman Rouzier,et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[100] P. Lønning,et al. Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study , 2003, BMJ : British Medical Journal.
[101] H. D. de Koning,et al. Trends in the usage of adjuvant systemic therapy for breast cancer in the Netherlands and its effect on mortality , 2004, British Journal of Cancer.
[102] E. Perez,et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. , 2004, The New England journal of medicine.
[103] M. Coleman,et al. Breast carcinoma survival in Europe and the United States , 2004, Cancer.
[104] Philip M. Long,et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[105] Umberto Veronesi,et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. , 2003, The New England journal of medicine.
[106] Syed Mohsin,et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.
[107] K. Bloom,et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. , 2003, The oncologist.
[108] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[109] R. Eils,et al. From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[110] M. West,et al. Gene expression predictors of breast cancer outcomes , 2003, The Lancet.
[111] A. Miller,et al. Why is breast-cancer mortality declining? , 2003, The Lancet. Oncology.
[112] M. J. van de Vijver,et al. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[113] J. Coebergh,et al. Breast Cancers Found by Screening: Earlier Detection, Lower Malignant Potential or Both? , 2002, Breast Cancer Research and Treatment.
[114] Nilanjan Chatterjee,et al. Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database , 2002, Breast Cancer Research and Treatment.
[115] N. Stoecklein,et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer , 2002, The Lancet.
[116] David Miles,et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[117] G. Q. della Rovere,et al. Ipsilateral local recurrence of breast cancer: determinant or indicator of poor prognosis? , 2002, The Lancet. Oncology.
[118] S. Dudoit,et al. Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data , 2002 .
[119] A. McTiernan,et al. Weight loss in breast cancer patient management. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[120] D. Haggstrom,et al. All-cause mortality in randomized trials of cancer screening. , 2002, Journal of the National Cancer Institute.
[121] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[122] N. Brünner,et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. , 2002, Journal of the National Cancer Institute.
[123] R. Spang,et al. Predicting the clinical status of human breast cancer by using gene expression profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[124] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[125] Robert J. Mayer,et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.
[126] Yudong D. He,et al. Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer , 2001, Nature Biotechnology.
[127] C. Giardina,et al. Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a long-term follow-up that were treated in a single institution. , 2001, European journal of cancer.
[128] P. Ravdin,et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[129] David A Jones,et al. Preservation of RNA for Functional Genomic Studies: A Multidisciplinary Tumor Bank Protocol , 2001, Modern Pathology.
[130] D. Rimm,et al. Validation of Tissue Microarray Technology in Breast Carcinoma , 2000, Laboratory Investigation.
[131] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[132] A E Giuliano,et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[133] M. Nooij,et al. [Adjuvant systemic therapy for patients with resectable breast cancer: guideline from the Dutch National Breast Cancer Platform and the Dutch Society for Medical Oncology]. , 2000, Nederlands tijdschrift voor geneeskunde.
[134] R. Elledge,et al. Tumor characteristics and clinical outcome of elderly women with breast cancer. , 2000, Journal of the National Cancer Institute.
[135] M. Schemper,et al. Predictive Accuracy and Explained Variation in Cox Regression , 2000, Biometrics.
[136] B. Angus,et al. A study of interval breast cancer within the NHS breast screening programme , 2000, Journal of clinical pathology.
[137] P. Porter,et al. Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. , 1999, Journal of the National Cancer Institute.
[138] M. Monden,et al. Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. , 1999, Nucleic acids research.
[139] B. Gusterson,et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer , 1999, The Lancet.
[140] H. Joensuu,et al. Long-term survival in node-positive breast cancer treated by locoregional therapy alone. , 1998, British Journal of Cancer.
[141] K Vajda,et al. [Prognostic factors in breast cancer]. , 1998, Orvosi hetilap.
[142] H. D. de Koning,et al. Nation‐wide breast cancer screening in The Netherlands: Results of initial and subsequent screening 1990–1995 , 1998, International journal of cancer.
[143] M. Kerin. Cancer principles and practice of oncology , 1997 .
[144] B A Miller,et al. Recent trends in U.S. breast cancer incidence, survival, and mortality rates. , 1996, Journal of the National Cancer Institute.
[145] T. Wobbes,et al. Interval carcinomas of the breast: A group with intermediate outcome , 1996, Journal of surgical oncology.
[146] R. Gray,et al. Annual hazard rates of recurrence for breast cancer after primary therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[147] F. Harrell,et al. Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .
[148] Ronald W. Davis,et al. Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.
[149] H. D. de Koning,et al. Nation‐wide breast cancer screening in the Netherlands: Support for breast‐cancer mortality reduction , 1995, International journal of cancer.
[150] M. MacDonald,et al. An Improved Approach to Prepare Human Brains for Research , 1995, Journal of neuropathology and experimental neurology.
[151] B. Fisher. The evolution of paradigms for the management of breast cancer: a personal perspective. , 1992, Cancer research.
[152] D. Page. Prognosis and Breast Cancer: Recognition of Lethal and Favorable Prognostic Types , 1991, The American journal of surgical pathology.
[153] C. Carter,et al. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989, Cancer.
[154] S Hellman,et al. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[155] R. Tarone,et al. Analysis of breast cancer mortality and stage distribution by age for the Health Insurance Plan clinical trial. , 1988, Journal of the National Cancer Institute.
[156] I. O. Ellis,et al. Confirmation of a prognostic index in primary breast cancer. , 1987, British Journal of Cancer.
[157] A R Feinstein,et al. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. , 1985, The New England journal of medicine.
[158] S. Koscielny,et al. Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. , 1984, British Journal of Cancer.
[159] C. Redmond,et al. Breast cancer estrogen and progesterone receptor values: their distribution, degree of concordance, and relation to number of positive axillary nodes. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[160] R. Blamey,et al. A prognostic index in primary breast cancer. , 1982, British Journal of Cancer.
[161] A. Luini,et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. , 1982, The New England journal of medicine.
[162] S. Shapiro,et al. Lead time in breast cancer detection and implications for periodicity of screening. , 1974, American journal of epidemiology.
[163] S. Shapiro,et al. Lead time gained by diagnostic screening for breast cancer. , 1968, Journal of the National Cancer Institute.
[164] H. Bloom,et al. Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.
[165] W. Halsted,et al. I. The Results of Operations for the Cure of Cancer of the Breast Performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. , 1894, Annals of surgery.
[166] S. Mook,et al. Prognostic factors in breast cancer: one fits all? , 2011 .
[167] Robert B Livingston,et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.
[168] Jack Cuzick,et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. , 2008, The Lancet. Oncology.
[169] M. Linver. 4–23 Pathologic Findings From the Breast Cancer Surveillance Consortium: Population-Based Outcomes in Women Undergoing Biopsy After Screening Mammography , 2007 .
[170] T. Eberlein. A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer , 2006 .
[171] E. Feuer,et al. SEER Cancer Statistics Review, 1975-2003 , 2006 .
[172] Marc Buyse,et al. Multi-centre independent validation of a gene prognostic signature for patients with node-negative breast cancer (BC) - final results , 2005 .
[173] I. Ellis,et al. The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.
[174] M. J. van de Vijver. Gene-expression profiling and the future of adjuvant therapy. , 2005, The oncologist.
[175] Debjani Dutta,et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. , 2004, The American journal of pathology.
[176] M. Radmacher,et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. , 2003, Journal of the National Cancer Institute.
[177] H. D. de Koning. Mammographic screening: evidence from randomised controlled trials. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[178] Van,et al. A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.
[179] René Bernards,et al. A progression puzzle. , 2002, Nature.
[180] R. Love. Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[181] ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. , 1999, Statistics in medicine.
[182] D. Botstein,et al. Exploring the new world of the genome with DNA microarrays , 1999, Nature Genetics.
[183] H. Sack. [Increasing incidence and declining mortality in breast carcinoma]. , 1997, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].
[184] J. Ranstam,et al. Increasing incidence of and declining mortality from breast carcinoma , 1997, Cancer.
[185] L. Penland,et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.
[186] K. Zedeler,et al. Medullary carcinoma of the breast, prognostic importance of characteristic histopathological features evaluated in a multivariate Cox analysis. , 1994, European journal of cancer.
[187] X. Zhang,et al. Interval breast cancers are not biologically distinct--just more difficult to diagnose. , 1994, American journal of surgery.
[188] R. Connor,et al. Stage-shift cancer screening model. , 1989, Journal of clinical epidemiology.
[189] Donald E. Henson,et al. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989 .
[190] D.,et al. Regression Models and Life-Tables , 2022 .